We evaluated the hospital evolution of hyponatremia and inflammation markers in patients with coronavirus disease 2019 (COVID-19). The hospital evolutions of a cohort of adult patients with COVID-19 pneumonia and hyponatremia were retrospectively analyzed. Data of the admission day, 2nd–3rd and 7th–10th day of hospitalization, and of the discharge day were collected. Comparative and multivariate analyzes were developed, and Hazzard ratio (HR) with 95% confidence intervals (95% CI) were calculated. Of the 172 hospitalized patients with COVID-19, 49 of them (28.5%) had hyponatremia, which were analyzed. A total of 32/49 (65.3%) patients were male, and 22/49 (44.9%) euvolemic. Mean age: 69.9 ± 14.7 years. All patients had high inflammatory markers at admission. Of the total patients with hyponatremia at admission, only 26.2% remained hyponatremic at the 7th–10th day of hospitalization. Improvement in serum sodium (SNa) coincided with improvement in inflammatory markers during hospitalization, in both euvolemic and hypovolemic hyponatremic patients. A higher serum creatinine at admission was independently associated with mortality (HR: 12.23, 95% CI: 2 to 25.6) in hyponatremic COVID-19 patients. In conclusion, both hypovolemic and euvolemic hyponatremia in COVID-19 patients occurred in an inflammation status, and improved as inflammation decreased.

Hypophysitis is a rare disease that consists of lymphocytic infiltration of the stalk and pituitary gland. It has been classified

BACKGROUNDHyponatremia is a frequent electrolytic disorder in hospitalized patients with Coronavirus Disease 2019 (COVID-19). Inflammatory status could be associated with hyponatremia in patients with COVID-19. We evaluate the hospital evolution of hyponatremia and inflammation markers in COVID-19 patients.METHODSA case-series of adult patients with COVID-19 pneumonia and hyponatremia at admission were included and retrospectively followed during hospitalization. Data of the volemic status, general characteristics, inflammation, and clinical outcomes, were collected and analyzed. Comparative and multivariate analyzes were developed, and Hazzard ratio (HR) with 95%-confidence intervals (95% CI) were calculated.RESULTS49 patients with hyponatremia followed, 32 (65.3) were male, and 22 (44.9%) euvolemic. Mean age: 69.9 ± 14.7 years. From the 100% of patients with hyponatremia at admission, only 26.2% remained hyponatremic at the 7th -10th hospitalization day. Improvement in serum sodium (SNa) coincided with improvement in inflammatory markers during hospitalization, as well as a decrease in the rate of hyponatremia. A lower SNa at admission was independently associated with mortality (HR: 12.23, 95%CI: 2 to 25.6).CONCLUSIONBoth admission hypovolemic and euvolemic hyponatremia in COVID-19 patients occurred in a inflammation status, and improved as inflammation markers decreased.